Charles Schwab
TIL icon

Charles Schwab’s Instil Bio TIL Stock Holding History

Charles Schwab’s Portfolio TIL Stock Details TIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,981
Closed -$201K – 3516
2024
Q3 		$201K Buy
+2,981
New +$70.2K ﹤0.01% 3338
2023
Q4 		– Sell
-2,981
Closed -$25.5K – 3568
2023
Q3 		$25.5K Sell
2,981
-15,650
-84% -$158K ﹤0.01% 3486
2023
Q2 		$205K Sell
18,631
-4,712
-20% -$57.6K ﹤0.01% 3303
2023
Q1 		$309K Buy
23,343
+1,102
+5% +$16.3K ﹤0.01% 3083
2022
Q4 		$280K Sell
22,241
-1,315
-6% -$65K ﹤0.01% 3130
2022
Q3 		$2.28M Buy
23,556
+12,241
+108% +$1.4M ﹤0.01% 2549
2022
Q2 		$1.05M Buy
11,315
+926
+9% +$131K ﹤0.01% 2773
2022
Q1 		$2.23M Buy
10,389
+329
+3% +$76.9K ﹤0.01% 2608
2021
Q4 		$3.44M Buy
10,060
+4,001
+66% +$1.54M ﹤0.01% 2535
2021
Q3 		$2.17M Buy
6,059
+137
+2% +$51.1K ﹤0.01% 2685
2021
Q2 		$2.29M Buy
+5,922
New +$2.2M ﹤0.01% 2671

Other funds holding TIL

CVV
Curative Ventures V Dallas, Texas $15.6M AUM 52.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Superstring Capital Management New York $140M AUM 323.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Charles Schwab's TIL Position: Q4 2024 in Review

Charles Schwab sold out of Instil Bio (TIL) in Q4 2024, closing a stake of 2,981 shares — an estimated $201K sold.

Charles Schwab first reported a position in TIL in Q2 2021 and held it in 11 quarters. The position peaked at $3.44M in Q4 2021. 40 funds tracked by Wall St. Rank hold TIL as of Q4 2024.

  • Charles Schwab reported no remaining Instil Bio position as of Q4 2024 after selling out during the quarter.
  • Charles Schwab sold 2,981 Instil Bio shares in Q4 2024, an estimated $201K.
  • Charles Schwab first reported a position in Instil Bio in Q2 2021 and held it in 11 quarters.
  • Charles Schwab's Instil Bio position peaked at $3.44M in Q4 2021.
  • 40 funds tracked by Wall St. Rank held Instil Bio as of Q4 2024.

Based on Charles Schwab's 13F filing for Q4 2024, filed 6 Feb 2025.